NVO vs. IESC

Last updated Jun 9, 2026

NVO (Novo Nordisk A/S) and IESC (IES Holdings, Inc.) are both stocks. NVO operates in Drug Manufacturers - General (Healthcare), while IESC operates in Engineering & Construction (Industrials). Over the past 10 years, NVO returned 6.20%/yr vs 48.95%/yr for IESC. At a 0.12 correlation, their price movements are largely independent.

Performance

NVO vs. IESC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novo Nordisk A/S (NVO) and IES Holdings, Inc. (IESC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NVO achieves a -16.56% return, which is significantly lower than IESC's 88.91% return. Over the past 10 years, NVO has underperformed IESC with an annualized return of 6.20%, while IESC has yielded a comparatively higher 48.95% annualized return.

NVO

• 1D: -4.52%
• 1M: -10.96%
• YTD: -16.56%
• 6M: -9.23%
• 1Y: -42.47%
• 3Y*: -17.53%
• 5Y*: 1.78%
• 10Y*: 6.20%

IESC

• 1D: 1.97%
• 1M: 10.23%
• YTD: 88.91%
• 6M: 66.06%
• 1Y: 162.49%
• 3Y*: 140.27%
• 5Y*: 69.06%
• 10Y*: 48.95%

*Multi-year figures are annualized to reflect compound growth (CAGR)

NVO vs. IESC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NVO Novo Nordisk A/S	-16.56%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%
IESC IES Holdings, Inc.	88.91%	93.58%	153.67%	122.72%	-29.76%	9.99%	79.42%	65.02%	-9.86%	-9.92%

Correlation

The correlation between NVO and IESC is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.16
Correlation (3Y) Calculated over the trailing 3-year period	0.16
Correlation (5Y) Calculated over the trailing 5-year period	0.14
Correlation (10Y) Calculated over the trailing 10-year period	0.12
Correlation (All Time) Calculated using the full available price history since Jan 28, 1998	0.12

Fundamentals

Market Cap NVO : $182.49B IESC : $14.83B
EPS NVO : $27.42 IESC : $18.85
PE Ratio NVO : 1.50 IESC : 38.98
PEG Ratio NVO : 0.06 IESC : 0.47
PS Ratio NVO : 0.56 IESC : 4.08
PB Ratio NVO : 0.90 IESC : 13.83
Total Revenue (TTM) NVO : $327.80B IESC : $3.63B
Gross Profit (TTM) NVO : $268.30B IESC : $931.31M
EBITDA (TTM) NVO : $181.54B IESC : $487.14M

Return for Risk

NVO vs. IESC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVO

NVO Risk / Return Rank: 12
NVO Sharpe Ratio Rank: 9
NVO Sortino Ratio Rank: 12
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 13
NVO Martin Ratio Rank: 17

IESC

IESC Risk / Return Rank: 92
IESC Sharpe Ratio Rank: 94
IESC Sortino Ratio Rank: 88
IESC Omega Ratio Rank: 88
IESC Calmar Ratio Rank: 96
IESC Martin Ratio Rank: 96

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVO vs. IESC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and IES Holdings, Inc. (IESC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NVO	IESC	Difference
Sharpe ratio: Return per unit of total volatility	-0.82	2.64	-3.46
Sortino ratio: Return per unit of downside risk	-1.01	2.84	-3.84
Omega ratio: Gain probability vs. loss probability	0.86	1.39	-0.53
Calmar ratio: Return relative to maximum drawdown	-0.77	7.50	-8.28
Martin ratio: Return relative to average drawdown	-1.14	21.33	-22.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NVO vs. IESC - Sharpe Ratio Comparison

The current NVO Sharpe Ratio is -0.82, which is lower than the IESC Sharpe Ratio of 2.64. The chart below compares the historical Sharpe Ratios of NVO and IESC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	NVO	IESC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.82	2.64	-3.46
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.05	1.29	-1.24
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.19	1.02	-0.83
Sharpe Ratio (All Time) Calculated using the full available price history	0.47	0.05	+0.41

Drawdowns

NVO vs. IESC - Drawdown Comparison

The maximum NVO drawdown since its inception was -74.70%, smaller than the maximum IESC drawdown of -98.32%. Use the drawdown chart below to compare losses from any high point for NVO and IESC.

Drawdown Indicators

	NVO	IESC	Difference
Max Drawdown Largest peak-to-trough decline	-74.70%	-98.32%	+23.62%
Max Drawdown (1Y) Largest decline over 1 year	-55.03%	-21.80%	-33.23%
Max Drawdown (3Y) Largest decline over 3 years	-74.70%	-49.23%	-25.47%
Max Drawdown (5Y) Largest decline over 5 years	-74.70%	-54.22%	-20.48%
Max Drawdown (10Y) Largest decline over 10 years	-74.70%	-54.28%	-20.42%
Current Drawdown Current decline from peak	-70.19%	-0.97%	-69.22%
Average Drawdown Average peak-to-trough decline	-17.77%	-55.01%	+37.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.21%	7.66%	+29.55%

Volatility

NVO vs. IESC - Volatility Comparison

The current volatility for Novo Nordisk A/S (NVO) is 9.75%, while IES Holdings, Inc. (IESC) has a volatility of 11.77%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than IESC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NVO	IESC	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.75%	11.77%	-2.02%
Volatility (6M) Calculated over the trailing 6-month period	38.30%	49.79%	-11.49%
Volatility (1Y) Calculated over the trailing 1-year period	52.08%	62.06%	-9.98%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	38.31%	53.94%	-15.63%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.56%	48.10%	-15.54%

Dividends

NVO vs. IESC - Dividend Comparison

NVO's dividend yield for the trailing twelve months is around 4.39%, while IESC has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
IESC IES Holdings, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.39%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Financials

NVO vs. IESC - Profitability Comparison

The chart below illustrates the profitability comparison between Novo Nordisk A/S and IES Holdings, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

IESC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, IES Holdings, Inc. reported a gross profit of 238.70M and revenue of 974.20M. Therefore, the gross margin over that period was 24.5%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

IESC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, IES Holdings, Inc. reported an operating income of 112.30M and revenue of 974.20M, resulting in an operating margin of 11.5%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.

IESC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, IES Holdings, Inc. reported a net income of 110.00M and revenue of 974.20M, resulting in a net margin of 11.3%.

Frequently Asked Questions

Can I hold both NVO and IESC in my portfolio?

NVO and IESC have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NVO or IESC?

IESC has higher volatility (11.77%) compared to NVO (9.75%). In terms of maximum drawdown, NVO dropped -74.70% vs IESC's -98.32%.

Which has better risk-adjusted returns?

IESC currently has the higher Sharpe Ratio (2.64 vs -0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.